Zivo Bioscience (ZIVO) Stock News

ZIVO Bioscience (OTCQB: ZIVO) signed a commercial-scale manufacturing agreement with Cyanotech Corporation on April 6, 2026 to grow, cultivate and process Zivolife™ proprietary algal biomass. The partnership provides scalable, cGMP-capable production at Cyanotech’s 96-acre NELHA facility with year-round cycles and GRAS-certified operations.

This step positions ZIVO to supply animal health, human nutrition and functional-ingredient customers and supports the company’s path toward initial commercial revenues.

ZIVO Bioscience (OTCQB: ZIVO) announced the Board intends to deregister its securities and cease SEC public reporting, citing high compliance costs and recurring dilution from capital raises. The company expects near-term AgTech revenue via a distribution partner that could enable positive cash flow and reduced operating costs. ZIVO reports progress in Animal Health due diligence, USDA-related Avian Influenza studies with the University of Georgia, increased production capacity for ZIVO LIFE microalgae, elimination of board compensation, and continued insider investment from the CEO.

ZIVO Bioscience (OTCQB: ZIVO) released a shareholder letter highlighting significant progress in human nutrition and animal health markets. The company's proprietary algae platform demonstrated breakthrough antioxidant performance, containing nearly double the Superoxide Dismutase (SOD) activity compared to competing products.

In animal health, ZIVO's algae-derived immune modulator showed promising results in poultry trials against avian influenza, demonstrating delayed transmission and lower viral shedding. The company is targeting substantial market opportunities, including the $465.65 billion global animal feed market and the $4.5 billion antibiotic-free livestock feed segment.

While facing liquidity challenges, ZIVO is pursuing capital raising efforts and expects significant near-term growth from new nutraceutical product commitments. The company is actively negotiating with major industry players and conducting additional confidential studies.

ZIVO Bioscience (OTCQB: ZIVO) has partnered with a leading global animal health company to advance its immune-enhancing compounds for poultry applications. The collaboration involves two key studies: a 42-day coccidiosis study to validate ZIVO's compound with the partner's vaccine, and a viral disease study to assess the compounds' effectiveness against high-mortality viral infections. Both studies, fully funded by the partner, will evaluate ZIVO's products' ability to enhance immune response, reduce immunization-to-immunity time, and protect birds during vulnerable periods. The partnership aims to expand into other livestock and companion animal markets, potentially creating a new non-antibiotic therapeutic platform. The studies will support USDA regulatory approval and validate the commercial business case.

ZIVO Bioscience (OTCQB: ZIVO) announced positive results from its second collaborative study with the University of Delaware testing formulations to combat Low Pathogenicity Avian Influenza (LPAI) in poultry. The study evaluated three different formulations of ZIVO's proprietary algal-derived ingredients, with the most promising being a blend of four distinct algal-derived materials that showed slower virus transmission. While direct challenge results showed modest positive trends in viral shedding reduction, the transmission study revealed potential protective effects. The company has submitted a $5.5 million funding request to the State of Michigan and is applying for the USDA's $100 million Avian Influenza Poultry Innovation Grand Challenge to advance their research.

ZIVO Bioscience (OTCQB: ZIVO) announces a second collaborative study with the University of Delaware to explore applications of its proprietary algal-derived ingredients in fighting Low Pathogenicity Avian Influenza (LPAI) virus in poultry. The announcement follows their previous successful study that showed significant reduction in viral shedding and delayed disease transmission in treated birds.

The new study aims to optimize formulations and treatment protocols for real-world poultry production environments. Several global animal health companies have expressed interest in ZIVO's non-antibiotic solutions, following positive results from both avian influenza and coccidiosis studies. The company's approach focuses on developing sustainable, cost-effective alternatives to traditional treatments using their proprietary algal cultures.

ZIVO Bioscience (OTCQB: ZIVO), a biotech/agtech R&D company focused on developing therapeutic, medicinal, and nutritional products from proprietary algal cultures, has announced its participation in The Microcap Conference 2025. The event will take place from January 28-30, 2025, in Atlantic City, New Jersey.

The company's management team will deliver a corporate presentation on Thursday, January 30, 2025, at 2:30 PM Eastern Time at Studio 1, Borgata Hotel Casino & Spa. During the conference, management will engage in one-on-one meetings with institutional and individual investors to discuss recent developments, growth strategy, and investment opportunities.

Zivo Bioscience has reported progress in licensing its coccidiosis treatment for broiler chickens. Following positive results from a 42-day study announced in August 2024, Zivo is discussing an exclusive license with major global animal health companies. Due diligence processes are underway, including technical evaluations, patent reviews, and business case assessments. Formal negotiations are expected to start in January 2025, with an agreement anticipated in Q1 2025. Zivo aims for a deal with upfront payment, milestone payments, and royalties. CEO John B. Payne highlighted the product's potential to enhance ionophores and vaccines. Additionally, Zivo is advancing its product targeting Low Pathogenicity Avian Influenza (LPAI) virus in poultry, planning further studies at the University of Delaware to optimize dosage and formulation. Payne noted the active ingredients' effectiveness against both parasitic and viral diseases, offering commercial opportunities.

ZIVO Bioscience (OTCQB: ZIVO) reports positive results from a University of Delaware study evaluating its proprietary active ingredients against Low Pathogenicity Avian Influenza (LPAI) in poultry. The two-part study showed statistically significant findings including reduced viral shedding in infected birds and delayed LPAI transmission when healthy birds were exposed to infected ones.

The study demonstrated that birds receiving ZIVO's ingredients experienced an early significant decrease in viral titers compared to untreated controls. Different product configurations showed varying effectiveness, with some better at lowering viral titer and others at slowing spread, suggesting potential for comprehensive protection through optimal product configuration.